The GLP-1 Revolution: Beyond Weight Loss
New trials in 2023 suggest GLP-1 agonists may have significant cardiovascular benefits, reshaping how we treat obesity-related diseases.
Clinical Trial Outcomes (SELECT Study 2023)
| Metric | GLP-1 Group | Placebo Group | Difference |
|---|---|---|---|
| Major Adverse Cardiovascular Events | 6.5% | 8.0% | 20% Relative Risk Reduction |
| Weight Loss at 104 Weeks | -9.4% | -0.9% | Significant |
Related: Pharma stocks, Peptide research, Medicare coverage, Global obesity, Health tracking apps, Heat stress, Medical schools, Drug pricing, Hospital capacity, Health outcomes, Cost of wellness, Diet culture, Athletic nutrition, Medical researchers, Preventative care, Insurance premiums, Clinical trials, FDA approvals, Pharma supply chains, Telemedicine, and Mental health.
Common Mistakes with GLP-1 Medications
- Assuming it's a temporary fix: Medical consensus treats obesity as a chronic condition; stopping medication usually results in weight regain.
Health FAQ
Does Medicare cover GLP-1 drugs for weight loss?
Currently, Medicare does not cover these drugs solely for weight loss, but may cover them for diabetes or cardiovascular risk reduction.
Next Step: Use our tool to check common insurance formularies.